<DOC>
	<DOCNO>NCT01248884</DOCNO>
	<brief_summary>This study design evaluate safety immunogenicity new formulation GSK Biologicals ' DTPa-HBV-IPV/Hib vaccine ( GSK217744 ) administer primary vaccination course healthy infant 2 , 3 4 month age .</brief_summary>
	<brief_title>Safety Immunogenicity New Formulations GlaxoSmithKline Biologicals ' DTPa-HBV-IPV/Hib Vaccine ( GSK217744 )</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol Amendment 1 , February 2011 , lead update exclusion criterion .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>A male female , include , 60 90 day age time first vaccination . Born gestation period 37 42 week inclusive . Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . Written inform consent obtain parent ( ) / Legally Acceptable Representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Administration vaccine foreseen study protocol , within 30 day prior first study visit , plan administration study period , exception oral rotavirus vaccination allow time study . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous intercurrent diphtheria , tetanus , pertussis , polio , hepatitis B , Hib and/or pneumococcal vaccination disease , exception hepatitis B vaccination birth . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History neurological disorder seizure . Administration immunoglobulins and/or blood product since birth plan administration study period . Acute disease and/or fever time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>combination vaccine</keyword>
	<keyword>Primary vaccination</keyword>
</DOC>